Moderna and Pfizer Investors: There's Room For Multiple mRNA Coronavirus Vaccine Winners
Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate. This news, paired with the equally impressive data from Moderna (NASDAQ: MRNA) about its candidate that takes a similar approach, inspired much hope around the world and injected optimism into the stock market.
The Motley Fool talked to Dr. Leo Nissola about what this hopeful development means for the world and for investors.
Source Fool.com